Deutsche Bank AG lifted its position in Stryker Corporation (NYSE:SYK - Free Report) by 22.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,438,910 shares of the medical technology company's stock after acquiring an additional 261,687 shares during the quarter. Deutsche Bank AG owned 0.38% of Stryker worth $453,026,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in SYK. VanderPol Investments L.L.C. increased its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC boosted its position in shares of Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock worth $653,000 after buying an additional 28 shares during the period. Rossby Financial LCC grew its holdings in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC grew its holdings in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after buying an additional 29 shares in the last quarter. Finally, West Michigan Advisors LLC increased its position in Stryker by 0.4% in the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock valued at $2,631,000 after acquiring an additional 30 shares during the period. Institutional investors own 77.09% of the company's stock.
Stryker Stock Down 2.2%
Shares of SYK stock opened at $331.75 on Tuesday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business's fifty day moving average is $325.21 and its 200-day moving average is $333.24. The stock has a market cap of $127.25 billion, a PE ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.
Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the firm posted $3.13 earnings per share. The company's revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is presently 36.48%.
Analyst Ratings Changes
A number of research analysts have issued reports on SYK shares. Evercore set a $350.00 price target on Stryker in a research report on Monday, July 6th. Citigroup reissued a "buy" rating on shares of Stryker in a report on Thursday. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective on the stock. Piper Sandler reduced their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Finally, Citizens Jmp decreased their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.
Check Out Our Latest Stock Analysis on SYK
Insider Activity
In related news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company's stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.60% of the company's stock.
About Stryker
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
